SK282517B6 - Deriváty fenylimidazolidínu, spôsob ich výroby a farmaceutický prostriedok s ich obsahom - Google Patents

Deriváty fenylimidazolidínu, spôsob ich výroby a farmaceutický prostriedok s ich obsahom Download PDF

Info

Publication number
SK282517B6
SK282517B6 SK769-93A SK76993A SK282517B6 SK 282517 B6 SK282517 B6 SK 282517B6 SK 76993 A SK76993 A SK 76993A SK 282517 B6 SK282517 B6 SK 282517B6
Authority
SK
Slovakia
Prior art keywords
carbon atoms
group
aryl
alkyl
alkoxy
Prior art date
Application number
SK769-93A
Other languages
English (en)
Slovak (sk)
Other versions
SK76993A3 (en
Inventor
Gerhard Zoller
Bernd Jablonka
Melitta Just
Otmar Klingler
Gerhard Breipohl
Jochen Knolle
Wolfgang K�Nig
Original Assignee
Cassella Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cassella Aktiengesellschaft filed Critical Cassella Aktiengesellschaft
Publication of SK76993A3 publication Critical patent/SK76993A3/sk
Publication of SK282517B6 publication Critical patent/SK282517B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/42Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/40Two or more oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK769-93A 1992-07-24 1993-07-21 Deriváty fenylimidazolidínu, spôsob ich výroby a farmaceutický prostriedok s ich obsahom SK282517B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4224414A DE4224414A1 (de) 1992-07-24 1992-07-24 Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung

Publications (2)

Publication Number Publication Date
SK76993A3 SK76993A3 (en) 1994-04-06
SK282517B6 true SK282517B6 (sk) 2002-10-08

Family

ID=6463969

Family Applications (1)

Application Number Title Priority Date Filing Date
SK769-93A SK282517B6 (sk) 1992-07-24 1993-07-21 Deriváty fenylimidazolidínu, spôsob ich výroby a farmaceutický prostriedok s ich obsahom

Country Status (16)

Country Link
US (1) US5424293A (ko)
EP (1) EP0580008B1 (ko)
JP (1) JP3775808B2 (ko)
KR (1) KR100418321B1 (ko)
AT (1) ATE168116T1 (ko)
AU (1) AU664630B2 (ko)
CA (1) CA2101179C (ko)
CZ (1) CZ289297B6 (ko)
DE (2) DE4224414A1 (ko)
DK (1) DK0580008T3 (ko)
ES (1) ES2119837T3 (ko)
HU (1) HU220767B1 (ko)
IL (1) IL106462A (ko)
SK (1) SK282517B6 (ko)
TW (1) TW306918B (ko)
ZA (1) ZA935341B (ko)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4308034A1 (de) * 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
DE4427979A1 (de) * 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
DE59706273D1 (de) * 1996-03-20 2002-03-21 Hoechst Ag Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
PL323130A1 (en) * 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647380A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6163155A (en) * 1999-01-28 2000-12-19 Dresser Industries, Inc. Electromagnetic wave resistivity tool having a tilted antenna for determining the horizontal and vertical resistivities and relative dip angle in anisotropic earth formations
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
JP2003502442A (ja) 1999-06-17 2003-01-21 ソース・プリシジョン・メディシン・インク セリンエラスターゼの活性を阻害する方法及び化合物
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) * 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
JP5060555B2 (ja) * 2006-07-11 2012-10-31 ハリバートン エナジー サービシーズ,インコーポレーテッド モジュラー式ジオステアリング用ツールアセンブリ
MX2008014830A (es) * 2006-07-12 2009-03-05 Halliburton Energy Serv Inc Metodo y aparato para construir una antena inclinada.
WO2008115229A1 (en) * 2007-03-16 2008-09-25 Halliburton Energy Services, Inc. Robust inversion systems and methods for azimuthally sensitive resistivity logging tools
WO2010074678A2 (en) 2008-12-16 2010-07-01 Halliburton Energy Services, Inc. Azimuthal at-bit resistivity and geosteering methods and systems
BRPI1013305B1 (pt) 2010-01-22 2019-09-10 Halliburton Energy Services Inc sistema para medir uma resistividade de uma formação, método para determinar uma resistividade,e, broca de perfuração instrumentada
WO2014003702A1 (en) 2012-06-25 2014-01-03 Halliburton Energy Services, Inc. Tilted antenna logging systems and methods yielding robust measurement signals
WO2016172496A1 (en) 2015-04-23 2016-10-27 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
HRP20231369T1 (hr) 2016-10-26 2024-02-16 Constellation Pharmaceuticals, Inc. Inhibitori lsd1 i njihova medicinska upotreba

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4126277A1 (de) * 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
DE4213634A1 (de) * 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate

Also Published As

Publication number Publication date
CZ147593A3 (en) 1994-03-16
SK76993A3 (en) 1994-04-06
ZA935341B (en) 1994-02-14
AU4211993A (en) 1994-01-27
IL106462A0 (en) 1993-11-15
ES2119837T3 (es) 1998-10-16
US5424293A (en) 1995-06-13
JPH0725855A (ja) 1995-01-27
CA2101179A1 (en) 1994-01-25
CA2101179C (en) 2003-10-28
TW306918B (ko) 1997-06-01
AU664630B2 (en) 1995-11-23
EP0580008B1 (de) 1998-07-08
DE59308732D1 (de) 1998-08-13
EP0580008A3 (de) 1995-03-15
HUT65141A (en) 1994-04-28
KR100418321B1 (ko) 2004-05-07
HU9302138D0 (en) 1993-10-28
KR940005583A (ko) 1994-03-21
IL106462A (en) 1997-02-18
DK0580008T3 (da) 1999-02-08
HU220767B1 (hu) 2002-05-28
ATE168116T1 (de) 1998-07-15
DE4224414A1 (de) 1994-01-27
CZ289297B6 (cs) 2001-12-12
JP3775808B2 (ja) 2006-05-17
EP0580008A2 (de) 1994-01-26

Similar Documents

Publication Publication Date Title
US5554594A (en) Imidazolidine derivatives
SK282517B6 (sk) Deriváty fenylimidazolidínu, spôsob ich výroby a farmaceutický prostriedok s ich obsahom
US5397796A (en) 2,4-dioxoimidazolidine compounds and compositions, and processes for administering same
US5658935A (en) Heterocycles, their preparation and their use
US5389614A (en) Hydantoin derivatives
KR100278532B1 (ko) 4-옥소-2-티옥소이미다졸리딘 유도체, 이의 제조방법 및 이를 포함하는 약제학적 제제
US5703050A (en) Urea derivatives, their preparation and use
US5681838A (en) Substituted amino compounds, their preparation and their use as inhibitors of thrombocyte-aggregation